2024 Volume 39 Issue 5 Pages 316-324
Comprehensive genomic profiling (CGP) in pancreatic cancer has advanced since its introduction in Japan in 2019. CGP has the potential to offer tailored therapies, yet challenges like inadequate tissue samples persist. Innovations in endoscopic techniques, device selection, and collaboration during EUS-FNA/B procedures are enhancing CGP's success rate. Recent strides in genomic and protein analysis using EUS-FNA/B specimens offer diagnostic promise, and ongoing progress in genome analysis holds the potential for treatment optimization and complements pathological diagnoses with minimal invasiveness. However, obtaining sufficient tissue for accurate assessment remains a frontline challenge. Despite the common use of EUS-FNA/B in tissue diagnosis, its limitations in detecting small lesions persist, emphasizing the need to balance precision and invasiveness in sampling. Embracing genomic medicine's role in therapy selection and aiding pathological diagnoses is crucial. Continued technical advancements, like liquid biopsy, offer hope for diagnosing challenging lesions. Integrating perspectives from gastroenterologists and pathologists is vital for navigating the complexities of CGP testing in pancreatic cancer and driving its clinical application.
